NCT02434354View on ClinicalTrials.gov

A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

July 31, 2019

Study Completion Date

September 29, 2021

Conditions
Malignant Melanoma
Interventions
DRUG

pembrolizumab

200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02434354 - A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | Biotech Hunter | Biotech Hunter